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ABSTRACT
Objective This study aimed to measure the impact of 
COVID-19 on the quality of life (QoL) of survivors and 
their partners and family members.
Design and setting A prospective cross- sectional 
global online survey using social media.
Participants Patients with COVID-19 and partners or 
family members (age ≥18 years).
Intervention Online survey from June to August 2020.
Main outcome measure The EuroQol group five 
dimensions three level (EQ- 5D- 3L) to measure the QoL 
of survivors of COVID-19, and the Family Reported 
Outcome Measure (FROM-16) to assess the impact on 
their partner/family member’s QoL.
Results The survey was completed by 735 COVID-19 
survivors (mean age=48 years; females=563) at a mean 
of 12.8 weeks after diagnosis and by 571 partners and 
164 family members (n=735; mean age=47 years; 
females=246) from Europe (50.6%), North America 
(38.5%) and rest of the world (10.9%). The EQ- 5D 
mean score for COVID-19 survivors was 8.65 (SD=1.9, 
median=9; range=6–14). 81.1% (596/735) reported 
pain and discomfort, 79.5% (584/735) problems 
with usual activities, 68.7% (505/735) anxiety and 
depression and 56.2% (413/735) problems with mobility. 
Hospitalised survivors (20.1%, n=148) and survivors 
with existing health conditions (30.9%, n=227) reported 
significantly more problems with mobility and usual 
activities (p<0.05), with hospitalised also experiencing 
more impact on self- care (p≤0.001). Among 735 
partners and family members, the mean FROM-16 
score (maximum score=highest impact =32) was 15 
(median=15, range=0-32). 93.6% (688/735) reported 
being worried, 81.7% (601/735) frustrated, 78.4% 
(676/735) sad, 83.3% (612/735) reported impact on 
their family activities, 68.9% (507/735) on sleep and 
68.1% (500/735) on their sex life.
Conclusion COVID-19 survivors reported a major 
persisting impact on their physical and psychosocial 
health. The lives of their partners and other family 
members were also severely affected. There is a need 
for a holistic support system sensitive to the needs 
of COVID-19 survivors and their family members who 
experience a major ‘secondary burden’.
INTRODUCTION
The COVID-19 pandemic is causing profound 
changes across the world, but there is little 
information on its physical and psychoso-
cial impact on survivors and their families. 
Despite the need1 for information on the 
lived experience of infected individuals and 
their family members, there are only sparse 
data available.
It is important to ascertain COVID-19’s 
immediate and persisting (long COVID-19) 
impact on those affected and on their fami-
lies in order to aid healthcare workers and 
government agencies to better support them. 
The understanding of how a person’s health 
condition impacts the quality of life (QoL) of 
other family members has increased over the 
last decade.2
The aim of this study was to assess the 
impact of COVID-19 on survivors and their 
family members based on their lived expe-
rience of COVID-19 using validated QoL 
instruments administered using online social 
media platforms.
Strengths and limitations of this study
 ► This study provides evidence of the impact on qual-
ity of life (QoL) of ‘long COVID-19’ in survivors of 
COVID-19.
 ► This study fills an important knowledge gap in mea-
suring the impact of survivors’ COVID-19 on the QoL 
of partners and other family members.
 ► Large sample size, heterogenous population and use 
of validated tools to assess QoL impact.
 ► The study was open to COVID-19 survivors and their 
family members internationally, but only those ac-
tive on social media who could read and understand 
English completed the survey.
 ► Causal relationships cannot be established among 
the study variables as the study was cross- sectional.
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This was a prospective cross- sectional global online survey, 
using an anonymous online questionnaire. The survey was 
carried out using https://www. onlinesurveys. ac. uk/ on a 
Jisc platform.3 The survey was distributed through social 
media platforms including Facebook, Twitter, LinkedIn, 
WhatsApp and Reddit.
Procedure
Study participants were provided with information about 
the study via a link in the survey to a ‘Participant Informa-
tion Sheet’, where they were informed that participation 
was voluntary and their data would remain anonymous. 
Those who decided to take part gave informed consent 
at the beginning of the survey. Data collection took place 
from 30 May to 30 August 2020.
The study was only open to individuals who were 
diagnosed with COVID-19 and their family member or 
partner, adults aged 18 years or above who could read 
and understand English and who were able to give written 
consent and complete the questionnaire using an elec-
tronic device. Participants were excluded if they had not 
had COVID-19 or if they were <18 years of age.
Survey development
The survey included two QoL questionnaires: EuroQol 
group five dimensions three level (EQ- 5D- 3L; in this 
study, for simplicity throughout this manuscript, we refer 
to EQ- 5D- 3L as ‘EQ- 5D’) and Family Reported Outcome 
Measure (FROM-16). There were additional sociodemo-
graphic questions such as responder’s age, gender and 
country of residence (table 1). A pretest draft survey 
was piloted during May 2020 in 20 individuals without 
COVID-19 across several countries including the UK, 
India and the UAE. Views were also sought from the study 
research partners, two patients and one family member. 
The survey questions were revised based on the collective 
feedback.
Patient and public involvement
Two patients and one family member were involved as 
integral study research partners, one of whom (SJN) is 
a coauthor. They were involved in reviewing the study 
protocol, drafting the survey, reviewing the manuscript 
and providing suggestions from the patient and family 
perspective.
Survey structure
The survey had two sections. Section 1 was completed 
by the COVID-19 survivor. Each survivor provided basic 
demographic details and provided EQ- 5D responses. 
Section 2 was completed by the partner or a family 
member of the survivor who provided basic demographic 
details and completed FROM-16. The survey did not 
specify whether this should be someone the patient lives 
with or whether it could be any close relation; however, 
the family member of the COVID-19 survivor was asked 
to specify their relationship to the patient.
Table 1 Sociodemographic characteristics of the study 
participants




Gender Male 172 (23.4%)
Female 563 (76.6%)
Age (years) Mean (SD) 47.77 (11.656)
Median 48.00
Range 19–85
Range (IQR) 19–85 (16)
Number of weeks since
COVID-19 diagnosis
Mean (SD) 12.76 (6.104)
Median 13.00
Range 1–36
Range (IQR) 1–36 (8)
≥4 weeks 98 (13.3%)
5–11 weeks 170 (23.1%)
≥12 weeks 467 (63.5%)
Occupation Unemployed 19 (2.6%)
In paid work 538 (73.2%)
In education or 
training
26 (3.5%)
In unpaid work 7 (1%)




Rather not say 19 (2.6%)
Existing health conditions No 508 (69.1%)
Yes 227 (30.9%)
Hospitalised for COVID-19 No 587 (79.9%)
Yes 148 (20.1%)
Regions Europe 372 (50.6%)
North America 283 (38.5%)
Rest of the world 80 (10.9%)
Family members (n=735)   
Gender Male 489 (66.5%)
Female 246 (33.5%)
Age (years) Mean (SD) 47.43 (13.582)
Median 48.00
Range 18–87
Occupation Unemployed 42 (5.7%)
In paid work 530 (72.1%)
In education or 
training
29 (3.9%)
In unpaid work 18 (2.4%)
Retired 95 (12.9%)
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Measurement tools
The EQ- 5D is a self- reported generic health- related QoL 
(HRQoL) instrument that specifically addresses health 
status.4 It consists of five questions on mobility, self- care, 
usual activities, pain and discomfort and anxiety and 
depression with 3- point response categories (1=no prob-
lems, 2=some problems and 3=serious or extreme prob-
lems). The EQ- visual analogue scale (VAS) component of 
EQ- 5D asks respondents to rate their overall health status 
from 0 (worst imaginable health) to 100 (best imaginable 
health).
The FROM-16 measures the impact of a patient’s disease 
on the QoL of a family member or partner of a patient.5 
The FROM-16 comprises 16 items with 3- point response 
options for each: not at all (scoring 0), a little1 and a lot,2 
with a total score range of 0–32. The higher the score, the 
greater the negative impact on the family member’s QoL. 
The 16 items are divided into two domains: emotional (6 
items, maximum score 12) and personal and social life 
(10 items, maximum score 20). The FROM-16 has proven 
psychometric properties, a rapid completion time of 2 
min5 and translations are available in several languages.6 
A generic measure, the FROM-16 has been validated 
across all areas of medicine5–7 and is therefore suitable 
for measuring the impact of COVID-19 on the partner 
and family members of those affected. As it is a generic 
measure, data generated can be compared with data from 
other medical conditions.
Outcome
The impact of COVID-19 on the quality of life of survivors 
and their partners and family members.
Exposure
COVID-19 infection of the participant or of the family 
member.
Covariates
The covariates included hospital stay due to COVID-19 
infection, existing health condition of survivors, number 
of weeks since COVID-19 diagnosis, partners and family 
members diagnosed with COVID-19, family members’ 
relationship to survivors, country of residence, age and 
sex of family members and survivors. All the covari-
ates, including hospitalisation, existing conditions and 
number of weeks since COVID-19 diagnosis were based 
on self- report.
Missing data
There were no missing data, but two responses were 
ambiguous for one of the variables (EQ- VAS) and were 
excluded from the analysis.
Statistical analysis
Descriptive statistics (ie, mean, SD, median, IQR) were 
performed for all variables. The Shapiro- Wilk test was 
used to examine normal distribution of continuous vari-
ables. The required assumptions for normal distribution 
were not met. Consequently, data analysis employed 
non- parametric statistical method. Both the EQ- 5D 
and the FROM-16 scores were treated in the analysis 
as dependent variables. The EQ- VAS component of 
EQ- 5D was examined separately as a dependent vari-
able. To determine differences between groups defined 
by each outcome, χ2 tests (when appropriate, Fisher’s 
exact tests) and Mann- Whitney U tests were computed. 
These bivariate comparisons were based on COVID-19 
survivor’s characteristics (gender, existing health condi-
tion and hospitalisation) and family member character-
istics (gender and whether diagnosed with COVID-19). 
Spearman’s rank correlation coefficient and multiple 
regression analysis were conducted to understand the 
effect of independent variables (ie, predictors: survivor 
age, existing health condition, hospital stay for COVID-
19, number of weeks since COVID-19 diagnosis, survivor 
gender) on the EQ- 5D outcomes. Similarly, these analyses 
were conducted to understand the effect of independent 
variables (EQ- 5D score, age family member, number of 
weeks since COVID-19 diagnosis, family member gender, 
whether family member also had COVID-19, relation-
ship to survivor, survivor age, survivor existing health 
condition, survivor hospital stay for COVID-19) on the 
FROM-16 outcomes. Statistical Product and Service Solu-
tions (V.25) was used and the probability of type I error 
was set at p<0.05.
RESULTS
Sociodemographic characteristics of the study participants
A total of 1254 respondents consented to participate in 
the survey: 765 completed both sections. Thirty responses 
were excluded as the respondents were below the age of 
18 years. The final analysis included 735 COVID-19 survi-
vors and their family members/partner from Europe 
(50.6%), North America (38.5%) and the rest of the 
world (10.9%) (table 1).
Of the 735 COVID-19 survivors, 76.6% were females 
(mean and median age=48 years) and 73.3% were in 
paid employment. The mean time since COVID-19 
symptoms started was 12.8 weeks (median=13 weeks). In 
86.6% (n=637), >4 weeks had elapsed since COVID-19 
symptoms started and in 63.5% (n=467) >12 weeks had 
elapsed. Of the family members (mean age=48 years, 
Variables Categories N (%) or N (SD)
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median=47 years), 66.5% were male and 72.1% were in 
paid employment. Most of the family members were part-
ners (77.7%), followed by sons and daughters (10.5%) 
and parents (6.5%). In addition, 48.3% of the family 
members had also contracted COVID-19 (table 1).
Quality of life impact of COVID-19 on survivors
The overall EQ- 5D mean score was 8.65 (SD=1.97) with 
the ‘usual activities’ item scoring the highest (mean=2.06, 
max=3) followed by pain/discomfort (1.93) and anxiety/
depression (1.84). The mean score of the visual analogue 
part of EQ- 5D was 56 (SD=22.94) (table 2).
Of the five dimensions of EQ- 5D, ‘pain and discomfort’ 
was the impact most frequently reported (81.1%; 68.7% 
some problems and 12.4% extreme problems), followed 
by usual activities (79.5%; 53.2% and 26.3%) and anxiety 
and depression (68.7%; 53.3% and 15.4%) (figure 1). 
There was a significant gender difference for ‘mobility’ 
and for ‘pain and discomfort’ (p≤0.05) with females 
being more impacted than males (table 3).
Although existing health conditions were self- reported 
and severity was not stated, survivors with existing health 
conditions did not appear to differ from those without 
such conditions except for mobility and usual activities 
(p≤0.05) (table 3). Having an existing health condi-
tion was not a clear predictor of impact on the family 
member/partner’s QoL. There was a significant differ-
ence between the survivors who had been hospitalised 
for COVID-19 (20%) and those who had not, with the 
hospitalised survivors being more severely affected across 
mobility, self- care (p≤0.001) and usual activities (p≤0.02) 
(table 3).
There were significant differences in overall EQ- 5D 
mean scores between survivors with respect to number of 
weeks since COVID-19 diagnosis (p<0.001). The overall 
EQ- 5D mean scores of survivors having COVID-19 symp-
toms for up to 4 weeks was 8.03 (SD=1.97), 5–11 weeks was 
8.3 (SD=2.13) and 12 weeks and above was 8.9 (SD=1.86).
Quality of life impact of COVID-19 on family members
The overall FROM-16 mean score was 15, reflecting the 
extent of the impact of the survivors’ COVID-19 on the 
HRQoL of their family members (table 2). The mean 
score of each of the 16 items is given in table 2 with 
‘feeling worried’ scoring highest (1.46) followed by family 
activities, frustration, holiday and sex life (1.26, 1.24, 1.10 
and 1.09, respectively) (table 2). Of the FROM-16 items, 
the feeling of being worried was most frequently reported 
(93.6%; 44.6% a little, 49% a lot), followed by family activ-
ities (83.3%; 41%, 42.3%), feeling of frustration (81.7%; 
39.7%, 42%), feeling sad (78.4%; 51.2%, 27.2%), sleep 
(68.9%; 37.1%, 31.8 %) and sex life (68.1%; 26.7%, 
41.4%) (figure 2).
There was a significant gender difference among family 
members, with females feeling more sad, experiencing 
more impact on everyday travel (p≤0.01) and on their 
sleep (p≤0.05). The impact on sex life was experienced 
significantly more by males than females (p≤0.001) 
(table 4).
Those with a COVID-19 history experienced a greater 
impact on eating habits, work and study, family activities, 
holiday (p≤0.05), sex life and sleep (p≤0.001). There 
were no significant differences for the remaining 10 items 
of FROM-16 (table 4).
There were significant differences in overall FROM-16 
mean scores between family members of survivors with 
respect to onset of COVID-19 symptoms (p<0.01). The 
overall FROM-16 mean scores of family members of survi-
vors having COVID-19 symptoms for up to 4 weeks was 
16.11 (SD=7.35), 5–11 weeks was 13.31 (SD=7.77) and 12 
weeks and above was 15.38 (SD=8.21).
Relationship between the quality of life of survivors and their 
family members
There were significant positive correlations between the 
EQ- 5D score and the survivors’ gender, hospital stay, existing 




EQ- 5D- 3L domains
  Overall score 8.65 (1.97) 9 (3) 6–14
  Mobility 1.59 (0.54) 2 (1) 1–3
  Self- care 1.23 (0.45) 1 (0) 1–3
  Usual activities 2.06 (0.68) 2 (1) 1–3
  Pain/Discomfort 1.93 (0.56) 2 (0) 1–3
  Anxiety/Depression 1.84 (0.67) 2 (1) 1–3
  EQ- VAS (n =733) 55.83 (22.94) 60 (35) 3–100
FROM-16
  Overall score 15.00 (8.05) 15 (13) 0–32
  Emotional domain 6.12 (3.23) 6.0 (5) 0–12
  Worried 1.43 (0.61) 1 (1) 0–3
  Angry 0.75 (0.73) 1 (1) 0–3
  Sad 1.05 (0.70) 1 (1) 0–3
  Frustrated 1.24 (0.74) 1 (1) 0–3
  Talking about thoughts 0.84 (0.79) 1 (1) 0–3
  Difficulty caring 0.81 (0.76) 1 (1) 0–3
  Personal and social 
domain
8.88 (5.51) 9.0 (9) 0–20
  Time for self 0.74 (0.76) 1 (1) 0–3
  Everyday travel 0.63 (0.78) 0 (1) 0–3
  Eating habits 0.65 (0.73) 0 (1) 0–3
  Family activities 1.26 (0.73) 1 (1) 0–3
  Holiday 1.10 (0.88) 1 (2) 0–3
  Sex life 1.09 (0.85) 1 (2) 0–3
  Work or study 0.84 (0.79) 1 (1) 0–3
  Family relationship 0.73 (0.76) 1 (1) 0–3
  Family expenses 0.83 (0.82) 1 (2) 0–3
  Sleep 1.01 (0.79) 1 (2) 0–3
EQ- 5D- 3L, EuroQol group five dimensions three level; FROM-16, 
Family Reported Outcome Measure; VAS, visual analogue scale.
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health condition and number of weeks since COVID-19 
diagnosis (p<0.05, p<0.001) (table 5).
There was a significant positive association between 
the family members’ FROM-16 scores and the survivors’ 
EQ- 5D scores (p<0.001) (table 5) and a significant nega-
tive association between FROM-16 scores and the family 
members’ age, survivors’ age and EQ- VAS scores (p<0.05).
The EQ- VAS scores showed a significant inverse rela-
tionship with EQ- 5D (p<0.01). However, other variables 
such as hospital stay, existing health condition and gender 
(being female) were associated with lower EQ- VAS scores 
(p<0.05), that is, lower health status (table 5).
Can quality of life predict outcomes?
The results of multiple regression analyses indicated that 
survivors’ demographics, number of weeks since COVID-19 
diagnosis and hospital stay were significant predictors of the 
extent of impact on QoL of the survivor (p=0.001) while 
the survivors' existing health condition was not a predictor 
(table 6). Inclusion of variables such as EQ- 5D scores, family 
members’ COVID-19 history, family members’ gender and 
relationship to the survivor in the model predicted family 
reported outcomes (p=0.001) while family members’ age, 

























































No problems Some problems Extreme problems
Figure 1 COVID-19 survivor response to EuroQol group five dimensions three level (EQ- 5D- 3L) (n=735).
Table 3 Comparisons† of EQ- 5D- 3L scores for gender, existing health condition and hospitalisation









P valueMale (n=172) Female (n=563) Yes (n=227) No (n=508) Yes (n=148) No (n=587)
Overall 8.33 8.74 0.036* 8.89 8.54 0.012* 9.17 8.51 0.001**
Mobility 1.51 1.61 0.037* 1.67 1.55 0.006** 1.75 1.54 0.0001**
Self- care 1.22 1.24 0.602 1.28 1.21 0.053 1.36 1.20 0.0001**
Usual activities 1.97 2.08 0.065 2.14 2.02 0.034* 2.19 2.02 0.009**
Pain/Discomfort 1.82 1.97 0.002** 1.93 1.94 0.989 1.99 1.92 0.141
Anxiety/Depression 1.81 1.85 0.611 1.88 1.82 0.289 1.88 1.83 0.427
**p ≤ 0.05, **p ≤ 0.01. (P- values were calculated using mean rank scoresbut mean scores are presented here for ease of understanding).
†Mann- Whitney U test.
EQ- 5D- 3L, EuroQol group five dimensions three level.
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existing health condition and hospital stay were not signif-
icant predictors of QoL of family members (table 7). The 
multiple regression analyses confirmed that the QoL of 
family members/partner was more impacted than survivors, 
female family members were affected more than males, 
family members with a history of COVID-19 were affected 
more than those without and partners were affected 
substantially more than those of other relationships. In 
addition, the model predicted that younger survivors’ func-
tional behaviour (both physical and psychosocial) was more 
impacted by COVID-19.
DISCUSSION
This study fills an important knowledge gap in measuring 
the impact of COVID-19 on the HRQoL of both the 
Figure 2 Partner and family member response to Family Reported Outcome Measure (FROM-16) items (n=735).







P valueMale (n=489) Female (n=246) Yes (n=355) No (n=380)
Overall 14.81 15.36 0.401 15.74 14.32 0.017*
Worried 1.40 1.48 0.068 1.46 1.39 0.135
Angry 0.73 0.79 0.332 0.77 0.74 0.519
Sad 1.00 1.16 0.004** 1.09 1.03 0.225
Frustrated 1.23 1.26 0.569 1.30 1.18 0.054
Talking about thoughts 0.83 0.87 0.651 0.89 0.80 0.132
Difficulty caring 0.79 0.85 0.324 0.81 0.80 0.847
Time for self 0.70 0.83 0.036* 0.78 0.71 0.164
Everyday travel 0.58 0.72 0.048* 0.64 0.62 0.874
Eating habits 0.64 0.67 0.565 0.72 0.59 0.015*
Family activities 1.28 1.21 0.144 1.32 1.20 0.041*
Holiday 1.10 1.10 0.992 1.17 1.03 0.030*
Sex life 1.22 0.84 0.000** 1.17 1.03 0.035*
Work or study 0.83 0.87 0.485 0.92 0.77 0.013*
Family relationships 0.69 0.79 0.109 0.75 0.70 0.281
Family expenses 0.81 0.87 0.367 0.84 0.83 0.759
Sleep 0.98 1.07 0.138 1.12 0.90 0.000**
*p ≤0.05, **p ≤ 0.01. (P values were calculated using meanrank scores but mean scores are presented here for ease of understanding).
†Mann- Whitney U test.
FROM-16, Family Reported Outcome Measure.
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survivors and, importantly, their partners and family 
members. HRQoL is defined as a person’s perception of 
his/her physical, mental, social and overall well- being.8 9 
Therefore, its assessment embraces a wider view of the 
impact of COVID-19.
This study has revealed that the pandemic has a major 
impact on lives of those who have survived the infection. 
The survey depended on the patient’s self- report of the 
diagnosis of COVID-19 infection and did not specifi-
cally ask whether patients had had a COVID-19- positive 
test. However, further authentication of the diagnosis 
was given by both the patient and their relative having 
answered the survey. Pain and discomfort were the most 
frequently reported problem by COVID-19 survivors, 
followed by impact on their usual activities, anxiety and 
depression, affecting females to a greater extent. As the 
majority of COVID-19 survivors were in paid employ-
ment, being physically unwell might have impacted their 
usual activities or return to work. According to a review 
on return to work after critical illness,10 globally, a third 
of previously employed survivors after intensive care stays 
remained out of work after 5 years.
In the survey, COVID-19 survivors were asked whether 
they were ‘already suffering from some existing chronic 
health condition (such as diabetes, heart disease, lung 
disease)’ prior to the infection with COVID-19. Survivors 
with existing health conditions did not differ significantly 
from those without such conditions except for mobility 
and usual activities however, having an existing health 
condition was not a significant predictor of impact on the 
family member/partner’s QoL. The survivor’s QoL was 
impacted greatly irrespective of having a existing health 
condition as it was not clear predictor of EQ- 5D scores 
in regression analysis. Hospitalised survivors reported 
greater impact on mobility, self- care and usual activities 
compared with those who had not been hospitalised. This 
survey did not ask respondents whether those hospital-
ised were admitted to intensive care unit (ICU). So we are 
not able to draw any conclusion concerning the relation-
ship of admission to ICU to later QoL.
The study also revealed a major impact on QoL of 
the survivors’ partners and family members with part-
ners being most impacted. Currently, Minimal Clinically 
Important Difference (MCID) for FROM-16 has not been 
published; however, MCID values for such questionnaires 
usually are approximately 10%–20% of the total score 
range, and so we would expect the FROM-16 MCID to 
be approximately 3–6. If this is the case, the statistically 
significant differences reported would also be clinically 
significant. Nearly half of participating partners and 
family members also reported having had COVID-19. 
Although there were no significant differences between 
the family members with COVID-19 and those without 
across 10 of the 16 QoL items of FROM-16, eating habits, 
family activities, holiday, sleep, sex life and work or study 
were impacted significantly more in those who had had 
COVID-19. Overall, FROM-16 scores were higher for part-
ners and family members with COVID-19 after adjusting 
for age, gender, relationship to survivor and the overall 
survivors’ EQ- 5D scores, thus indicating poorer QoL for 
family members with COVID-19 than for those without.
Most partners and family members reported being 
worried and frustrated, many reported sadness, inability 
to talk to someone and difficulty in caring for their loved 
ones. This is not surprising in a situation with constant 
media coverage with emphasis on high daily death rates, 
the fear of infecting loved ones, stigma due to community 
or family members blaming survivors for the spread of 
the illness, isolation of loved ones, inability of a family 
member to provide support and prolonged recovery 
time.11 Such stressors have been implicated in the poor 
psychological and emotional health of survivors and their 
family members.11–14
Family members reported an impact on sexual life 
as a result of their relative’s COVID-19 and this impact 
was higher in males and in family members who has also 















0.058 0.051 8.907 0.0001
Survivor age −0.013 0.006 −0.076 0.043 −0.025 0.000
Existing health condition 0.298 0.157 0.070 0.059 −0.011 0.607
Hospital stay for COVID-19 0.644 0.181 0.131 0.0001 0.288 1.001
Number of weeks since COVID-19 
diagnosis
0.050 0.012 0.154 0.0001 0.027 0.073
Male gender −0.471 0.169 −0.101 0.005 −0.802 −0.139
*Multiple regression; B=the slope of the line between the predictor variable and the dependent variable—the larger the number, the more spread out 
the points are from the regression line; F- test=degree of the linear regression model fitting the data; R2=how well the model fits the data; males=1 
and females=0; females are the reference group.
EQ- 5D- 3L, EuroQol group five dimensions three level.
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contracted COVID-19. Two- thirds of family members 
were either spouses or partners, who could have experi-
enced these difficulties because of the contagious nature 
of COVID-19 and because of postsurvival symptoms. 
Moreover, physical illness in partners has a significant 
impact on marital relationships, contributing to marital 
dissatisfaction and likelihood of later divorce.15 Over half 
of partners and family members reported impact on holi-
days and nearly half reported an increase in expenses due 
to their relative’s COVID-19.
One of the key findings of this study is the evidence 
that in survivors in whom the COVID-19 onset was >12 
weeks ago, there was still a major persisting impact on 
QoL across all domains in both survivors and family 
members. This provides further evidence of the severe 
impact of post- acute COVID-19 (‘long COVID-19’) and 
‘chronic COVID-19’.16 According to the National Insti-
tute for Health and Care Excellence, the term ‘long 
COVID-19’ ‘is commonly used to describe signs and symp-
toms that continue or develop after acute COVID-19. It 
includes both ongoing symptomatic COVID-19 (from 4 
to 12 weeks) and post- COVID-19 syndrome (12 weeks or 
more)’.17 The term ‘persisting’ refers to the continuity 
of the impact of COVID-19 on survivor’s health since the 
onset of COVID-19 infection.
Interestingly, of the patients who participated, most 
(76.6%) were women, as found in other surveys18; 
however, there was a higher proportion of men among 
participating family members (66.5%). This may be 
because the majority of COVID-19 social media support 
groups have been initiated by women (patients), and the 
most convenient family person to ask to participate might 
be their partners (mostly male).
Comparison with other studies
Chinese survivors of COVID-19 reported lower HRQoL 
with significant impact on their physical and psycholog-
ical health, 1 month after recovery.19 Our study has shown 
a major impact on the HRQoL of survivors of COVID-19 
and on their partners and family members. This is consis-
tent with the findings of Golics et al2 20 that multiple 
elements of family members’ lives can be affected by a 
relative’s illness including emotional, financial, family 
relationships, education and work, leisure time, and 
social activities.
Our study has shown that most (87%) survivors had 
COVID-19 for >4 weeks, and 64% >12 weeks indicating that 
survivors continued to remain unwell for long periods of 
time, due to postviral symptoms or ‘long COVID-19’. This 
is in contrast to a UK COVID-19 symptom study,21 where 
only 10% of COVID-19- positive survivors remained unwell 
at 3 weeks, and a small proportion for >3 months. An 
online survey of British doctors in August 2020 revealed 
that many were being treated for long- term COVID-19 
symptoms such as chronic fatigue, muscle weakness, loss 
of sense of smell and concentration difficulties.22
In our study, 69% COVID-19 survivors reported feel-
ings of anxiety and depression, much higher than the 
43.1% reported by Ma et al9 in clinically stable patients 
with COVID-19. Previous studies of SARS revealed the 
persistence of depression in patients up to 30 months 
after discharge from hospital.23 24
Several studies have shown the impact of COVID-19 
on sleep patterns of survivors, with an increase in preva-
lence of insomnia.25–27 We do not know whether the sleep 
patterns of survivors in our study were also impacted, 
since EQ- 5D does not include such an item. However, in 
our study 69% of partners and family members experi-
enced problems with sleep, and 32% reported that their 
sleep was impacted ‘a lot’.
The domain mean scores for FROM-16 in this study were 
6.1 (emotional) and 8.9 (personal and social life), which 
are higher than the mean domain scores reported by 
Golics et al5 (emotional=5.6; personal and social life=6.7) 
on the impact of patients’ chronic disease on family 
members across 26 medical specialties. Another study4 
reported the mean domain scores of family members of 
patients with cancer as emotional=4.7 and personal and 
social life=7.1. In a FROM-16 study on family members of 
patients with urinary stone disease, family members were 
not impacted much by their relative’s disease, however 
they reported a slightly greater degree of change in the 
‘emotional’ domain compared with the ‘personal and 
social life’ domain.28 This indicates that family members of 
COVID-19 survivors suffered more than family members 
of patients with other severe chronic diseases.
Strengths and limitations
This study to our knowledge is the first global study to 
explore the impact of COVID-19 on both survivors and 
also their family members/partner. Other strengths 
include the large sample size, heterogenous population 
and use of validated tools to assess QoL impact. The study 
has demonstrated use of the FROM-16 questionnaire for 
studying the effects of a pandemic on family members of 
an infected person.
This study has several limitations. First, it suffers from 
considerable selection bias as only those COVID-19 survi-
vors and family members who could access the internet 
and were active on social media completed the online ques-
tionnaires, limiting generalisability of the study findings. 
It is also possible that people who experienced persisting 
symptoms may have been more likely to have participated 
in the study. This survey was conducted internationally 
in the English language. Although FROM-16 is available 
to researchers in several languages, our full survey docu-
ments and the participant information sheet were only 
available to the participants in the English language, 
and in the survey FROM-16 was also only provided in 
English. Participants could only take part if they could 
understand all of the documentation. The ability of some 
respondents to read and understand English may have 
been limited, but we are not able to assess this. However, 
during the development of, in particular, FROM-16, the 
following issues were considered as part of its concep-
tualisation and development in order to improve its 
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universality and translatability: (1) applying readability to 
the level of understanding of a 12- year old; (2) formatting 
of the items into short and complete sentences of about 
six words to enhance clarity of meaning; (3) ensuring 
ease of understanding to allow future cross- cultural 
adaptation, facilitating universality and translatability. 
Although we did not develop the EQ- 5D, that question-
naire was also designed to be as universally understand-
able as possible. Concerning the wider survey questions, 
we took several steps in the development of the survey 
to ensure maximum comprehensibility: (1) we ensured 
that the readability was acceptable to a 12- year old stan-
dard; (2) we carried out an international pilot including 
participants for whom English was not their first language 
and made adjustments accordingly; (3) the survey was 
reviewed by our patient study research partners.
Second, the study, being cross- sectional, cannot estab-
lish causal relationships among the study variables. 
Because of the nature of the study, we could not collect 
any baseline measurements (pre- COVID-19 measure-
ments). We are, therefore, not able to differentiate 
between the effect of COVID-19 infection or of a pre- 
existing physical or mental state. However, only 30.9% 
of respondents had any existing health condition, and 
therefore this limitation only refers to this small propor-
tion of respondents. In addition, as all the covariates in 
the study were self- reported, data on hospitalisation and 
medical problems could be inaccurate and is a potential 
limitation.29 This study does not have a control group 
but in healthy volunteers in the UK, mean EQ- 5D scores 
were EQ- VAS=82.75, mobility=0.18, self- care=0.04, usual 
activity=0.16, pain/discomfort=0.33, anxiety/depres-
sion=0.20.30 In contrast, COVID-19 survivors (47.1% 
of survey respondents were from the UK) in our study 
had mean scores of EQ- VAS=55.83, mobility=1.59, self- 
care=1.23, usual activity=2.06, pain/discomfort=1.93, 
anxiety/depression=1.84. This suggests that overall 
HRQoL was highly impaired in the COVID-19 survivors 
across all domains. Furthermore, the study was carried 
out between June and August 2020 when the severity of 
the pandemic varied among different countries. There-
fore, the study results may have been influenced by 
the specific local and governmental measures in place 
at the time. It is likely that participants will have been 
living under different government restrictions, thereby 
possibly influencing responses to the questionnaires. 
However, because of the complexity of the international 
situation, we are not able to account for this. Although 
formal cultural adaptation of the survey questionnaire 
was not carried out, we endeavoured to ensure maximum 
understandability and acceptability. It should be noted 
that the questions asked are mostly universal in nature 
and do not refer to culturally specific practices such as 
semantic differences. However, despite these limitations, 
the study has provided a rapid overview of survivors’ and 
their family members’ HRQoL and revealed evidence of 
the substantial persisting effect on QoL of survivors and 
a major secondary impact on the lives of partners and 
family members. This information can be used to inform 
policymakers about the health needs of these individ-
uals and may encourage the development of tailor- made 
support services.
Implications for clinicians and policymakers
Our results have shown how the impact of COVID-19 on 
one family member can have a domino effect on other 
family members, especially those close to them such as 
partner, parents and children. It is important to under-
stand the needs of these impacted family members and 
survivors to ensure the overall well- being of the family unit. 
Based on the findings of this study, policymakers should 
consider developing and commissioning the following 
support services for survivors and family members:
 ► Post COVID-19 clinics: survivors reported pain and 
discomfort even after 12 weeks of COVID-19, indi-
cating that tailored services to deal with such symp-
toms are important to help survivors suffering with 
long term sequelae. Survivors with post- COVID-19 
complications should be heard and treated. Although 
such clinics have been started in a few countries, there 
is a considerable need for such initiatives globally.
 ► Needs- based mental health counselling: most family 
members and survivors reported being depressed 
and worried. It is imperative to further develop care 
services to ensure the mental well- being of survivors 
and their family members.
 ► Physical activity and rehabilitation services: most survivors 
have reported pain and discomfort and an inability to 
do their normal activities. Rehabilitation clinics could 
provide emotional and physical support to physically 
and emotionally drained survivors and their family 
members to enable their return to normal routines.
 ► Social support services: patients with COVID-19 are from 
diverse backgrounds and therefore will benefit from 
culturally and socially appropriate support. Finan-
cial assistance is particularly important for those who 
do not have health insurance to cover COVID-19 
expenses.
 ► Patient support groups/local support groups for COVID-19 
survivors and family members: local support groups 
could be used in primary care settings and can help by 
significantly combating isolation and the disability the 
study has identified that occurs in COVID-19 survivors 
and their family members/partners. This could in turn 
have health economic benefits by possibly reducing 
long- term utilisation of mental health services. Similar 
approaches have been successful, for example, in 
supporting people with myalgic encephalitis.
Future research and recommendations
Although this study provided an overview of the impact 
of COVID-19 on survivors’ partners and family members, 
it was not designed to identify causal relationship. Future 
longitudinal studies are needed to understand the long- 
term impact of COVID-19. As COVID-19 is still a major 
challenge, with people experiencing ‘long COVID-19’, 
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there is a need for further research including long- term 
studies to better understand ‘long COVID-19’ and its 
impacts on survivors and family members. However, the 
way the participants were recruited for the current study 
does not allow us to have access to follow- up data from 
this cohort. We were unable to measure the impact of 
COVID-19 on sleep and sex life of survivors, future studies 
should measure such impacts.
CONCLUSION
Survivors of COVID-19 report a major persisting impact 
on their QoL with many feeling unwell beyond 12 weeks. 
This indicates a demand for a holistic support system that 
is sensitive to their needs. Moreover, the QoL of partners 
and family members is also severely impacted, demon-
strating the importance of investigating disease impact 
on family QoL. The establishment of services to provide 
support to family members of survivors and patients in 
general is therefore a key consideration in the future 
management of COVID-19. Although the recruitment 
method used inevitably leads to some degree of selection 
bias which in turn may dilute the generalisability of the 
study findings, the central conclusions of this study that 
COVID-19 has a profound and long- lasting impact on 
survivors and their family members continue to remain 
valid.
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